跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 179 条关于
“Enspryng (satralizumab)”
全部
179
临床试验
159
药物
8
机构
0
资讯
12
2个月前
FDA Grants Priority Review to Roche's Enspryng as First At-Home Subcutaneous Therapy for Thyroid Eye Disease
去年
FDA Blocks Approval of AstraZeneca's Ultomiris for Neuromyelitis Optica Spectrum Disorder
9天前
FDA Grants Priority Review to Roche's Enspryng for MOGAD, With Decision Due January 2027
5个月前
ENSPRYNG Achieves 68% Reduction in MOGAD Relapses in Pivotal Phase III Trial
10个月前
Satralizumab Demonstrates 17.4% Reduction in Pulmonary Vascular Resistance in Biomarker-Selected PAH Patients
去年
Long-Term Safety of Omaveloxolone in Friedreich Ataxia Highlighted
上个月
IL-6 Receptor Blockers Show Promise for Preventing Relapses in Rare Autoimmune Neurological Disorder MOGAD
上个月
Obinutuzumab Beta Posts 93.1% Relapse Reduction in AQP4+ NMOSD, Joining a Crowded Efficacy Plateau
去年
TEPEZZA Sales Surge as Thyroid Eye Disease Treatment Market Expands to $2.3 Billion
去年
New Real-Time Imaging Method Advances Therapeutic Antibody Immunogenicity Risk Assessment
第 1 页,共 2 页
上一页
下一页